GetTopicDetailResponse(id=2fc71538911, topicName=RET基因突變或融合, introduction=RET基因突變或融合, content=null, image=null, comments=1, allHits=984, url=https://h5.medsci.cn/topic?id=15389, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=103262, tagList=[TagDto(tagId=103262, tagName=RET基因突變或融合)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1951893, encodeId=9a60195189372, content=<a href='/topic/show?id=2fc71538911' target=_blank style='color:#2F92EE;'>#RET基因突變或融合#</a>, objectTitle=FDA批準(zhǔn)了針對(duì)RET基因突變或融合癌癥的藥物--Retevmo, objectType=article, longId=193857, objectId=f26b19385e5c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f26b19385e5c, replyNumber=0, likeNumber=74, createdTime=2020-12-29, rootId=0, userName=lancelotzzl, userId=4f32220, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f26b19385e5c, moduleTitle=FDA批準(zhǔn)了針對(duì)RET基因突變或融合癌癥的藥物--Retevmo, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=f26b19385e5c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
